Low Counts of B Cells, Natural Killer Cells, Monocytes, Dendritic Cells, Basophils, and Eosinophils are Associated with Postengraftment Infections after Allogeneic Hematopoietic Cell Transplantation  by Podgorny, Peter J. et al.
Biol Blood Marrow Transplant 22 (2016) 37e46Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgBiology: BiomarkersLow Counts of B Cells, Natural Killer Cells, Monocytes,
Dendritic Cells, Basophils, and Eosinophils are Associated
with Postengraftment Infections after Allogeneic
Hematopoietic Cell TransplantationPeter J. Podgorny 1,*, Laura M. Pratt 1, Yiping Liu 1, Poonam Dharmani-Khan 1, Joanne Luider 2,
Iwona Auer-Grzesiak 2, Adnan Mansoor 2, Tyler S. Williamson 1, Alejandra Ugarte-Torres 1,
Mette Hoegh-Petersen 1, Faisal M. Khan 2, Loree Larratt 3, Victor H. Jimenez-Zepeda 1,
Douglas A. Stewart 1, James A. Russell 1, Andrew Daly 1, Jan Storek 1
1Department of Medicine, University of Calgary, Calgary, Alberta, Canada
2Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada
3Department of Medicine, University of Alberta, Edmonton, Alberta, CanadaArticle history:
Received 4 June 2015
Accepted 2 September 2015
Key Words:
Immune cells
Monocytes
Infections
Hematopoietic
TransplantationFinancial disclosure: See Acknowle
* Correspondence and reprint re
Calgary, 3330 Hospital Drive NW, C
E-mail address: podgorny@ualb
http://dx.doi.org/10.1016/j.bbmt.20
1083-8791/ 2016 American Sociea b s t r a c t
Hematopoietic cell transplant (HCT) recipients are immunocompromised and thus predisposed to infections.
We set out to determine the deﬁciency of which immune cell subset(s) may predispose to postengraftment
infections. We determined day 28, 56, 84, and 180 blood counts of multiple immune cell subsets in 219
allogeneic transplant recipients conditioned with busulfan, ﬂudarabine, and Thymoglobulin. Deﬁciency of a
subset was considered to be associated with infections if the low subset count was signiﬁcantly associated
with subsequent high infection rate per multivariate analysis in both discovery and validation cohorts. Low
counts of monocytes (total and inﬂammatory) and basophils, and low IgA levels were associated with viral
infections. Low plasmacytoid dendritic cell (PDC) counts were associated with bacterial infections. Low
inﬂammatory monocyte counts were associated with fungal infections. Low counts of total and naive B cells,
total and CD56high natural killer (NK) cells, total and inﬂammatory monocytes, myeloid dendritic cells (MDCs),
PDCs, basophils and eosinophils, and low levels of IgA were associated with any infections (due to any
pathogen or presumed). In conclusion, deﬁciencies of B cells, NK cells, monocytes, MDCs, PDCs, basophils,
eosinophils, and/or IgA plasma cells appear to predispose to postengraftment infections.
 2016 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematologic malignancies and benign disorders of
hematopoiesis are often cured with allogeneic hematopoi-
etic cell transplantation (HCT). However, HCT recipients are
immunocompromised because of multiple factors such as a
relatively small number of immune cells transferred with
the graft, limited differentiation of the grafted hematopoietic
stem cells into some immune cell subsets like T cells,
and pharmacologic immunosuppression. Therefore, HCT
recipients are at a substantial risk of infections, causing
morbidity and mortality. This immunocompromised statedgments on page 45.
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ty for Blood and Marrow Transplantation.lasts for at least 1 year [1-5]. Known predictive factors for
high infection rates include an unrelated or HLAmismatched
related donor (compared with a matched sib donor), cord
blood or marrow graft (compared to mobilized blood stem
cell graft), T celledepleted graft, and the presence of signif-
icant graft-versus-host disease (GVHD) [5-7]. However, these
known predictive factors cannot reliably distinguish
between patients who will or will not develop infections.
Thus, the discovery of new predictive markers is of interest.
Low count of an immune cell subset could be a useful
marker for subsequent infections. More important, associa-
tion between a low immune cell subset count and subse-
quent infections may help us understand the mechanism by
which patients are rendered susceptible to infections. In
addition, if it was known which immune cell subset
deﬁciency predisposes to infections, the risk of infections
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subset from the donor, except if a high count of the subset
could predispose to GVHD (eg, T cells) [8]. Whereas neu-
tropenia appears to be the cardinal predisposing factor for
early (pre-engraftment) infections, little is known about
the deﬁciency of which immune cell subset(s) predisposes
to postengraftment infections [9,10]. This knowledge is
completely lacking for the setting of in vivo T cell depletion
with polyclonal rabbit antithymocyte globulin, which
has been increasingly used to prevent GVHD [11-15]. We
set out to determine, in the setting of antithymocyte
globulineconditioned HCT, the low counts of which immune
cell subsets on days 28, 56, 84, or 180 are associated with
high rates of subsequent infections.
METHODS
Patients and Transplantation
Heparinized blood was collected from 231 patients who had undergone
ﬁrst allogeneic marrow or mobilized blood stem cell transplantation in Cal-
gary between December 1, 2004 and August 31, 2010 and agreed to partici-
pate in this Research Ethics Boardeapproved study. Twelve patients were
excluded because of graft failure, death, or relapse before day 30. The
remaining 219 patients were divided into a discovery cohort (transplant date
between December 1, 2004 and August 31, 2008) and a validation cohort
(transplant date between September 1, 2008 and August 31, 2010) (Table 1).
Patients received myeloablative conditioning, typically ﬂudarabine
(250 mg/m2 i.v.), busulfan (approximately 12.8 mg/kg i.v.), and antithymo-
cyte globulin (4.5 mg/kg i.v.), and additional GVHD prophylaxis with
methotrexate (days 1, 3, 6, and 11) and cyclosporine from day e1 until 3 to
6 months post-transplant or longer in the case of chronic GVHD [16]. Con-
ditioning of some patients included total body irradiation (TBI) (4 Gy) [17].
Clinically signiﬁcant GVHD (grades II to IV acute GVHD or chronic GVHD
needing systemic therapy) was treated with a corticosteroid  other
immunosuppressive drug(s). Supportive care was similar for all patients. No
antibacterial or antifungal prophylaxis was given routinely (except for
trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis). Pneumo-
cystis prophylaxis was given until 6 months post-transplant or longer (in the
case of chronic GVHD needing systemic therapy). Acyclovir was used until
6 to 12 months post-transplant or longer (in the case of chronic GVHD
needing systemic therapy).
All blood products were from cytomegalovirus- (CMV) seronegative
donors and were leukocyte depleted. CMV DNAemia was monitored;
preemptive therapy was used [18]. Monitoring of Epstein-Barr virus
DNAemia was not done, neither was monitoring for any other virus apart
from CMV. Follow-up for infections ended at the time of death, graft failure,
relapse, second malignancy, last contact, or day 730, whichever occurred
ﬁrst. Median follow-up for infections was 730 days (range, 34 to 730 days).
Immune Cell Subset Enumeration
The blood for enumeration of immune cell subsets was drawn on
approximately days 28, 56, 84, and 180 after HCT (Table 1). The counts of
most subsets were determined by ﬂow cytometry as described [8] and
deﬁned as shown in Supplementary Table 1. Total WBC, eosinophil, and
neutrophil counts were determined by a clinical hematology laboratory
(Calgary Laboratory Services, Calgary, Alberta, Canada or other accredited
laboratory). As a surrogate of total body plasma cell count and function, IgM,
IgG, and IgA serum levels were measured by a clinical laboratory on days 84
and 180 post-transplant (typically using automated immunoturbidimetry
analyzer, Integra 800; Roche Diagnostics, Mannheim, Germany). Patients
who received IgG supplementation within 2 months before a time point
were excluded from analysis of the association between IgG level on that
time point and subsequent infections. The median counts of the cell subsets
at the studied time points have been published [19] and for convenience are
also given in Table 2.
Deﬁnitions of Infections
Deﬁnite infection was deﬁned as an illness with symptoms and
signs consistent with an infection and microbiologic documentation of a
pathogen. For zoster virus, clinical diagnosis was considered sufﬁcient.
Microbiologic documentation included isolation of the pathogen by culture
from a sterile site or a nonsterile site (if from a nonsterile site, the organism
had to be clinically judged as pathogenic) or histologic/immunohistologic
evidence. Culture-documented bacteremia or fungemia was counted even
in the absence of symptoms or signs of infection, unless the organism
was clinically judged as contaminant. CMV reactivation was counted as aviral infection only if treated (preemptively or because of presumed or
documented CMV disease) [18]. Post-transplant lymphoproliferative disor-
der was counted as a viral infection and was deﬁned as an illness with signs
or imaging results consistent with post-transplant lymphoproliferative
disorder (eg, fever not due to other causes, lymphadenopathy, splenomeg-
aly, or a mass) with Epstein-Barr virus DNA above 400 copies/mg leukocyte
DNA or in situ hybridization/immunohistologic evidence of post-transplant
lymphoproliferative disorder.
Presumed (clinical) infection was deﬁned as illness with symptoms and
signs consistent with an infection and no microbiologic documentation of a
pathogen. However, presumed oral, gastrointestinal, conjunctival, and
respiratory tract infections were discounted because they could not be
reliably distinguished from GVHD or allergy. Fever without other symptoms/
signs was also discounted because it could not be reliably attributed to an
infection. Hemorrhagic cystitis was discounted because it could not be
differentiated from conditioning regimeneinduced cystitis. Sinusitis and
pneumonia were counted only if radiologically documented.
A recurrent infection was counted as multiple infections if the episodes
were separated by more than a 4-week asymptomatic period. A chronic
infection (with asymptomatic periods lasting 4 weeks) was counted as
1 infection. A polymicrobial infection of 1 organ or several adjacent organs
was counted as 1 infection. An infection in 2 nonadjacent organs because
of the same microorganism was counted as 1 infection (disseminated).
Severe infectionwas deﬁned as infection resulting in hospitalization. For
infections occurring during hospitalization, severe infection was deﬁned as
infection that would result in hospitalization if the patient was an
outpatient.
Infection rate was deﬁned as the number of infections per 365 days at
risk within a post-transplant time interval. Infection rates were assessed for
any infections (deﬁnite or presumed), any severe infections (severe deﬁnite
or severe presumed), severe deﬁnite infections, viral infections, bacterial
infections, and fungal infections.STATISTICS
Spearman rank correlation was used to evaluate correla-
tions between the counts of each immune cell subset
at predeﬁned time points and the rate of infections in
subsequent time intervals (eg, for day 84, intervals of days
84 to 179, 84 to 364, and 84 to 730 were considered;
Supplementary Figure 2). For each immune cell subset for
which the count appeared to be signiﬁcantly associated with
an infection rate in a subsequent time interval (P < .05), a
multivariate analysis (MVA) was performed as Poisson
regression, comparing infection rates in patients with high
versus low subset counts. Cutoff betweenhigh and lowcounts
of an immune cell subset was determined using receiver-
operator characteristic curves as the point with the highest
sum of speciﬁcity and sensitivity for developing at least 1
infection in the interval. In caseswhere thepointof thehighest
sum of speciﬁcity and sensitivity fell outside of the 10th to
90th percentile, the point of the highest sumof speciﬁcity and
sensitivity within the 10th to 90th percentile was used. The
MVA was done to adjust for factors that could predispose to
infections (other than the cell subset count). The covariateswe
includedwere signiﬁcant GVHD (grades II to IV acute GVHDor
chronic GVHD needing systemic therapy) in that interval (yes
or no), donor type (HLA-matched sibling versus other), and
stem cell source (marrow versus blood stem cells).
In the Poisson regression, days at risk were used as the
offset. In the MVA, P < .01 was considered signiﬁcant. This
was an arbitrary correction for multiple comparisons; the
correction was far less strict than Bonferroni correction
because we assumed that counts of the various immune cell
subsetswere partly related to each other. For every association
signiﬁcant in the discovery cohort, the association was
analyzed by MVA in the validation cohort. To be considered
validated, the association must have been signiﬁcant at
P < .05 in the validation cohort. Additionally, the median
percentile of the rate of infections in the low subset count
group had to be equal or higher than that in the high subset
Table 1
Patient Characteristics
Characteristic Discovery Cohort (n ¼ 133) Validation Cohort (n ¼ 86) Signiﬁcance of Difference*
Median patient age, yr 47 (range, 19-66) 50 (range, 19-66) .164
Median donor age, yr 35 (range, 15-67) 37 (range, 12-68) .786
Patient sex 79 M, 54 F (59% M, 41% F) 50 M, 36 F (58% M, 42% F) .853
Donor sex 89 M, 44 F (67% M, 33% F) 48 M, 38 F (56% M, 44% F) .097
Diagnosis/disease stage at transplanty .933
Poor risk 58 (44%) 38 (44%)
Good risk 75 (56%) 48 (56%)
Diagnosis .007
AML in ﬁrst remission 42 (32%) 27 (31%)
AML beyond ﬁrst remissionz 16 (12%) 10 (12%)
ALL in ﬁrst remission 10 (8%) 12 (14%)
ALL beyond ﬁrst remission 5 (4%) 5 (6%)
CML in ﬁrst chronic/accelerated phase 8 (6%) 0
CML in blast or second chronic/accelerated phase 2 (w1%) 0
CMML 5 (4%) 0
CLL 2 (w1%) 7 (8%)
Non-Hodgkin lymphoma 21 (16%) 7 (8%)
Hodgkin lymphoma 2 (w1%) 0
Myelodysplasia/myeloﬁbrosis 14 (11%) 17 (20%)
Aplastic anemia 4 (3%) 0
Otherx 2 (w1%) 1 (1%)
Stem cell source .020
Bone marrow 8 (6%) 0
Blood stem cells 125 (94%) 86 (100%)
Donorerecipient CMV serostatus at HCT .687
Positiveepositive 37 (28%) 28 (33%)
Positiveenegative 11 (8%) 7 (8%)
Negativeepositive 30 (23%) 19 (22%)
Negativeenegative 54 (41%) 27 (31%)
Unknown or indeterminate 1 (w1%) 5 (6%)
Donorerecipient EBV serostatus at HCT .106
Positiveepositive 117 (88%) 65 (76%)
Positiveenegative 4 (3%) 7 (8%)
Negativeepositive 9 (7%) 9 (10%)
Negativeenegative 0 1 (1%)
Unknown or indeterminate 3 (2%) 4 (5%)
Conditioning (in addition to antithymocyte globulin) .058
Fludarabine þ busulfan 44 (33%) 27 (31%)
Fludarabine þ busulfan þ TBI 81 (61%) 59 (69%)
Otherk 8 (6%) 0
Donor type .460
HLA-matched sibling 64 (48%) 37 (43%)
Other{ 69 (52%) 49 (57%)
Median day of engraftment# 14 (range, 10-27) 14 (10-24) .537
Graft failure after day 30 1 (w1%) 0 .420
Acute GVHD by grade .301
None 59 (44%) 33 (38%)
Grade I 38 (29%) 32 (37%)
Grade II 23 (17%) 12 (14%)
Grade III 12 (9%) 5 (6%)
Grade IV 1 (w1%) 2 (2%)
Indeterminate 0 1 (1%)
Chronic GVHD
None 72 (54%) 44 (51%) .091
Not needing systemic therapy 13 (10%) 15 (17%)
Needing systemic therapy 48 (36%) 27 (32%)
Relapse 26 (20%) 18 (21%) .868
Second malignancy** 11 (8%) 5 (6%) .495
Death 41 (31%) 27 (31%) .929
Median follow-up (days post-transplant)yy
For infections 730 (range, 38-730) 730 (range, 34-730) .385
For infections among patients without relapse/
graft failure/second malignancy/death by day 730
730 (range, 92-730) 730 (range, 68-730) .895
For death 835 (range, 59-1657) 883 (range, 44-1448) .374
For death among surviving patients 1018 (range, 181-1532) 1010 (range, 68-1448) .569
Actual median blood draw days post-transplant
Day 28 28 (range, 23-36) 27 (range, 24-34) .025
Day 56 56 (range, 50-68) 55 (range, 51-64) .172
Day 84 84 (range, 77-105) 83 (range, 75-96) .029
Day 180 182 (range, 160-200) 181 (range, 159-207) .860
Number of patients with immune cell subsets enumerated
Day 28 113 81 Not applicable
Day 56 114 78 Not applicable
(Continued on next page)
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Table 1
(continued)
Characteristic Discovery Cohort (n ¼ 133) Validation Cohort (n ¼ 86) Signiﬁcance of Difference*
Day 84 112 74 Not applicable
Day 180 74 57 Not applicable
AML indicates acute myeloid leukemia; ALL, acute lymphoid leukemia; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; CLL, chronic
lymphocytic leukemia; EBV, Epstein-Barr virus.
* Signiﬁcance of difference was determined by Mann-Whitney-Wilcoxon test for ordinal variables and by chi-square test for nominal variables.
y Good risk disease was deﬁned as acute leukemia in ﬁrst remission, CML in ﬁrst chronic or accelerated phase, myelodysplasia with <5% marrow blasts, or
aplastic anemia. All other diseases/disease stages were considered poor risk.
z Includes any AML that evolved from myelodysplasia or myeloﬁbrosis.
x Acute undifferentiated leukemia (n ¼ 1, discovery cohort), unclassiﬁable myeloproliferative syndrome (n ¼ 1, discovery cohort), and myeloproliferative
syndrome (n ¼ 1, validation cohort).
k Combinations of cyclophosphamide, etoposide, melphalan, or TBI.
{ 10/10- (HLA-A, -B, -C, -DRB1, -DQB1) allele matched unrelated donors (n ¼ 48 discovery cohort, n ¼ 40 validation cohort), 9/10-allele matched unrelated
donors (n ¼ 18 discovery, n ¼ 7 validation), 8/10-allele matched unrelated donors (n ¼ 2 discovery, n ¼ 1 validation), 10/10-allele matched related nonsibling
donors (n ¼ 0 discovery, n ¼ 1 validation), or 9/10- allele matched related donors (n ¼ 1 discovery, n ¼ 0 validation).
# The ﬁrst of 3 consecutive days with absolute neutrophil count .5/nL.
** Including post-transplant lymphoproliferative disorder. Excluding nonmelanoma skin cancer and carcinoma in situ.
yy Follow-up for infections was until relapse, graft failure second malignancy, death, or last contact, whichever occurred ﬁrst. The reason for ending follow-up
at relapse, graft failure, or secondmalignancywas that the treatment of relapse, graft failure, or secondmalignancy inﬂuences the risk of infections. Follow-up for
death was until death or last contact, whichever occurred ﬁrst.
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subset group had to be higher (similar criteria would have
applied to subsets forwhich ahigh countwas associatedwitha
high infection rate; however, such subsets were not found).
Analysis was carried out using StataIC, version 11 (StataCorp
2009; Stata Statistical Software: Release 11;College Station, TX).
For most subsets that were associated with infections in a
speciﬁc time interval, the association was between the sub-
set count and any infections or deﬁnite infections (and notTable 2
Median Counts of Cell Subsets (Per mL Blood)*
Subset Day 28 Day 56 Day
84
Day
180
Day
365y
B cells 2.8 40.6 35.1 106.0 175.5
Naive B cells 1.1 35.6 30.7 92.9 156.6
Memory B cells,
nonswitched
.5 1.4 1.2 2.3 1.9
Memory B cells,
switched
.3 .7 1.0 2.7 4.4
CD4 T cells 21.7 78.3 89.8 113.8 216.0
Naive CD4 T cells .1 .3 .5 2.6 10.8
Memory or effector CD4
T cells
21.5 76.8 88.0 100.8 169.6
CD8 T cells 33.7 287.2 248.7 298.8 271.1
Naive CD8 T cells .4 1.0 1.0 1.9 4.2
Memory or effector
CD8 T cells
32.6 276.5 246.2 297.1 271.1
CD4CD8 T cells 11.0 23.3 23.1 32.3 27.5
CD4þCD8þ T cells 2.8 11.6 20.5 23.8 7.5
Regulatory CD4 þ T cells .4 .8 1.7 2.8 5.0
NKT cells, invariant
(iNKT cells)*
.6 .6 .8 .8 .8
NK cells 319.0 256.7 201.4 161.6 163.9
CD16 CD56high NK cells 46.5 16.3 13.3 7.6 6.8
CD16þ CD56low NK cells 93.2 113.2 96.1 85.0 83.9
CD16highCD56 NK cells 22.4 34.4 36.2 22.9 2.0
Monocytes 589.4 336.5 398.2 363.0 396.7
Inﬂammatory
monocytes
433.1 256.4 268.2 258.0 312.1
Resident monocytes 134.8 75.1 90.6 76.0 84.9
MDCs 2.0 1.3 3.6 4.1 4.7
PDCs 3.6 1.5 1.5 1.2 3.1
Basophils 19.9 8.1 5.6 3.6 23.1
Eosinophils 100.0 100.0 100.0 100.0 d
Neutrophils 3000.0 2600.0 2400.0 2700.0 3300.0
WBCs 4500.0 4700.0 4300.0 4900.0 5400.0
NKT indicates natural killer T cells d, not recorded.
* Discovery and validation cohorts combined.
y Median counts for the day 365 timepoint for NKT cells are only for
discovery cohort; validation cohort counts were not measured.speciﬁcally viral, bacterial, or fungal infections). This was
likely due to the limited power of the analysis for viral,
bacterial, and fungal infections, because any infections or
deﬁnite infections far outnumbered viral, bacterial, or fungal
infections. Thus, for each subset associated with any in-
fections or deﬁnite infections (in a time interval), we com-
bined the discovery and validation cohorts to ascertain with
a higher power (higher than in either discovery or validation
cohorts alone) whether there was an association between
the subset and viral, bacterial, or fungal infections. If yes
(MVA P < .05), these results are preceded with a “?” symbol
in Supplementary Tables 2 through 6 (to indicate that the
certainty of association is relatively low because it could not
be validated in a separate validation cohort).RESULTS
Infection Rates
A total of 535 infections (deﬁnite and presumed) occurred
between days 28 and 730 in the 219 patients (in discovery
and validation cohorts combined) over 111,188 days at risk.
The average rate of any (deﬁnite or presumed) infection was
8.01 per 365 days at risk between days 28 and 55, 4.51 per
365 days at risk between days 56 and 83, 2.27 per 365 days
at risk between days 84 and 179, 1.22 per 365 days at
risk between days 180 and 364, and .86 per 365 days at risk
between days 365 and 730 (Table 3 and Supplementary
Figure 2). Analogous rates of deﬁnite infections, viral in-
fections, bacterial infections, fungal infections, any severe
infections, and severe deﬁnite infections are shown in Table 3
and Supplementary Figure 2.
To determine which clinical/demographic factors inﬂu-
enced the risk for infections in our population, we performed
an MVA to determine the association between patient age
(<45 versus 45 years), matched sibling versus other donor,
HLA match (10/10 matched versus 9/10 matched), graft
type (marrow versus peripheral blood stem cells), signiﬁcant
GVHD (at any time), and infection rates in the longest in-
tervals days 28 to 364 and 56 to 730. We found that only
signiﬁcant GVHD at any time was signiﬁcantly associated
with infections (see Supplementary Figure 5).Lymphocyte Subsets Associated with Infections
For total B cells, low day 180 counts were associated
with a high rate of any infections between days 180 and
Table 3
Rates of Infections within Time Intervals
Time Intervals Any Deﬁnite Viral Bacterial Fungal Any Severe Severe Deﬁnite
One interval Days 28-55 8.01 7.53 6.07 1.27 .24 4.55 4.37
Days 56-83 4.51 4.19 2.58 1.42 .45 2.77 2.64
Days 84-179 2.27 2.02 1.18 .61 .24 .92 .84
Days 180-364 1.22 .99 .59 .29 .12 .41 .37
Days 365-730 .86 .67 .33 .24 .12 .35 .31
Two intervals Days 28-83 6.31 5.91 4.38 1.34 .34 3.69 3.53
Days 56-179 2.81 2.54 1.52 .81 .29 1.36 1.27
Days 84-364 1.61 1.37 .81 .41 .17 .60 .55
Days 180-730 .99 .79 .42 .26 .12 .37 .34
Three intervals Days 28-179 3.87 3.56 2.45 .90 .28 2.01 1.90
Days 56-364 1.91 1.67 1.00 .51 .20 .83 .77
Days 84-730 1.22 1.01 .56 .32 .14 .47 .43
Four intervals Days 28-364 2.52 2.26 1.51 .59 .20 1.20 1.13
Days 56-730 1.40 1.18 .67 .38 .16 .59 .54
Average rates of any infections (deﬁnite or presumed), deﬁnite infections, viral infections, bacterial infections, fungal infections, any severe infections and severe
deﬁnite infections per 365 days at risk are given for the time intervals for which statistical analyses were carried out. The top 5 intervals are the basic (short)
intervals (“1 interval”). The following 4 intervals are longer, each consisting of 2 neighboring basic intervals (“2 intervals”). The following 3 intervals are even
longer, each consisting of 3 neighboring basic intervals (“3 intervals”). The following 2 intervals are the longest, each combining 4 neighboring basic intervals (“4
intervals”). Discovery and validation cohorts were combined for this analysis.
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(Supplementary Table 2 and Supplementary Figure 3). This
association may have been primarily due to the association
between low counts of total B cells and viral infections
(signiﬁcant in combined discovery and validation cohort).
For naive B cells, which constitute most blood B cells in
both healthy and post-transplant individuals [19], low
counts were associated with high rates of any, deﬁnite, any
severe, and severe deﬁnite infections. Both viral and bac-
terial infections appeared to be increased in the patients
with low naive B cell counts. For memory B cells, no as-
sociation with an infection rate was found. For CD4 and
CD8 T cells and their subsets and for invariant natural killer
(NK) T cells, no association with an infection rate was
found.
For total NK cells, low day 56 counts were signiﬁcantly
associated with high rates of any infections in the day 56 to
364 time interval (Supplementary Figure 3). Both viral and
bacterial infections appeared to be increased in the patients
with low total NK cell counts. For CD16CD56high NK cells,
which constitute a minority subset of blood NK cells in both
healthy and post-transplant individuals [19], low day 56
counts were associated with high rates of both any and
deﬁnite infections and appeared to be associated with
high rates of viral, bacterial, and fungal infections. ForP = .007
Figure 1. Low monocyte count on day 56 associated with subsequent viral infections.
56 monocyte counts above and below receiver-operator characteristic determined
monocyte counts are given in number of cells per mL.CD16þCD56low NK cells, which is the most numerous subset
of circulating NK cells [19], no association with an infection
rate was found.
Monocytes/Monocyte Subsets Associated with Infections
Inﬂammatory monocytes are the majority subset
and resident monocytes the minority subset of mono-
cytes in both healthy and post-transplant individuals
(Supplementary Table 3) [19]. Low counts of both total
and inﬂammatory monocytes on day 56 were associated
with high rates of any (Supplementary Figure 3), deﬁnite,
viral (Figures 1 and 2), and, possibly, bacterial infections.
Also, low counts of total monocytes on day 56 were
associated with high rates of severe and severe deﬁnite
infections. Low counts of inﬂammatory monocytes on day
56 were associated with high rates of fungal infections.
Additionally, on day 84 inﬂammatory monocytes were
found to be possibly associated with viral, bacterial, and
fungal infections. For resident monocytes, no association
with an infection rate was found.
Dendritic Cell Subsets Associated with Infections
Low myeloid dendritic cell (MDC) counts on days
28, 56, and 84 were associated with high rates of
any (Supplementary Table 4 and Supplementary Figure 3),P = .016
Rates of day 56 to 730 viral infections per 365 days at risk in patients with day
cutoff are displayed. Shown are the medians and interquartile ranges. Cutoff
P = .003
P = .001 P < .001
P = .001
Figure 2. Low inﬂammatory monocyte count on day 56 associated subsequent viral and fungal infections. Rates of day 56 to 730 viral and fungal infections per
365 days at risk in patients with day 56 inﬂammatory monocyte counts above and below receiver-operator characteristic determined cutoff are displayed. Shown are
the medians and interquartile ranges. Cutoff inﬂammatory monocyte counts are given in number of cells per mL.
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be associated with viral, bacterial, and fungal infections.
Low plasmacytoid dendritic cell (PDC) counts on day 56
were associated with high rates of any (Supplementary
Figure 3) and bacterial infections (Figure 3) and, possibly,
viral and fungal infections. Low PDC counts on day 84 were
associated with deﬁnite and severe deﬁnite infections and,
possibly, viral, bacterial, and fungal infections.P < .001
Figure 3. Low PDC count on day 56 associated with subsequent bacterial infections. R
day 56 PDC counts above and below receiver-operator characteristic determined cut
count is given in number of cells per mL.Granulocyte Subsets Associated with Infections
Low basophil counts on day 56 were associated with
high rates of deﬁnite (Supplementary Figure 3) and viral
infections (Figure 4). Low basophil counts on day 84 were
associated with high rates of deﬁnite and any severe in-
fections (Supplementary Table 5).
Low eosinophil counts on day 56 were associated with
high rates of any (Supplementary Figure 3) and deﬁniteP = .012
ates of day 56 to 730 bacterial infections per 365 days at risk in patients with
off are displayed. Shown are the medians and interquartile ranges. Cutoff PDC
P = .001 P < .001
Figure 4. Low basophil count on day 56 associated with subsequent viral infections. Rates of day 56 to 730 viral infections per 365 days at risk in patients with day 56
basophil counts above and below receiver-operator characteristic determined cutoff are displayed. Shown are the medians and interquartile ranges. Cutoff basophil
count is given in number of cells per mL.
P.J. Podgorny et al. / Biol Blood Marrow Transplant 22 (2016) 37e46 43infections and, possibly, viral and bacterial infections. There
was no association between neutrophil counts on days 28,
56, 84, or 180 and an infection rate.
WBC Counts and Infections
There was no association between total WBC counts on
days 28, 56, 84, or 180 and an infection rate.
Immunoglobulin Serum Levels Associated with Infections
Low IgA levels on day 84 were associated with high
rates of any (Supplementary Figure 3), deﬁnite, and viral
infections. There was no association between IgM or IgG
levels on day 84 or 180 and an infection rate (Supplementary
Table 6).
Correlations among Subsets
A limitation of our study is that if low counts of several
subsets at 1 time point were associated with infections,
it was impossible to determine whether deﬁciency of all
subsets predisposed to infections versus whether deﬁciency
of only 1 or a few of the subsets predisposed to infections
(where low counts of the remaining subsets were only sur-
rogates for the low counts of the subsets predisposing to
infections). This problem did not pertain to day 28, because
only 1 subset on day 28 was associated with infections
(MDCs). This problem also did not pertain to day 180,
because only 2 related subsets (B cells and IgA levels as
surrogates for IgA plasma cells) were associated with
infections. There was a correlation between day 180 B cell
counts and IgA levels (Spearman rank correlation coefﬁcient
r ¼ .46, P ¼ .001), which is expected because B cells are
expected to differentiate into IgA plasma cells. However, this
problem pertained only to the day 56 and 84 time points.
On day 56, there was a signiﬁcant correlation among all
subsets associated with any or deﬁnite infections (ie, total
and CD56high NK cells, total and inﬂammatory monocytes,
MDCs, PDCs, basophils, and eosinophils) (Supplementary
Table 7). However, the correlation coefﬁcients were rela-
tively low (.16 to .67, apart from the expected association
between total and inﬂammatory monocytes), suggesting an
independent contribution of each subset to the predisposi-
tion to infections. Similarly, on day 84 there was a relatively
weak (correlation coefﬁcients .06 to .65) but signiﬁcant
correlation among most subsets associated with any or
deﬁnite infections (Supplementary Table 8). Nevertheless,there was no correlation between naive B cells and inﬂam-
matory monocytes, between basophils and inﬂammatory
monocytes, between naive B cells and IgA, between inﬂam-
matory monocytes and IgA, or between MDCs and IgA. This
suggested independent contribution to predisposition to
infections of the subsets in these pairs of subsets.Cell Subset Count in Patients with High and Low Infection
Rates
To further display the relationship between subset
counts and infection rates (beyond that shown in Table 3
and Supplementary Figures 2 and 3), we show the kinetics
of reconstitution of all signiﬁcant cell subsets (subsets
associated with infections) in patients with high versus low
infection rates (Supplementary Figure 4).DISCUSSION
We discovered and validated associations between low
counts of several immune cell subsets and high rates of
postengraftment infections. The subsets that were associated
and thus appear to predispose to the infections include
B cells (total and naive), NK cells (total and CD16CD56high),
monocytes (total and inﬂammatory), MDCs, PDCs, basophils,
eosinophils, and IgA plasma cells.
Low B cells, especially the naive subset, appeared to
predispose to any, deﬁnite, any severe, severe deﬁnite, and,
probably, viral and bacterial infections (Supplementary
Table 2), and low IgA levels appeared to predispose to any,
deﬁnite, any severe, and viral infections (Supplementary
Table 6 and Figure 5). Naive B cells should, after encoun-
tering their cognate antigen and appropriate costimulation,
differentiate into memory B cells and plasma cells. It may be
that with more naive B cells present on or after day 84, there
is a higher number of B cells prepared to detect various
pathogens and differentiate into the unique plasma cells,
producing antibodies needed to curtail the pathogens via
neutralization, complement-mediated lysis, or opsonized
phagocytosis. Consistent with that, on post-hoc analysis
there was a correlation or a trend towards a correlation
between day 84 naive B cell counts and day 84 IgM, IgG, and
IgA levels (r ¼ .21, .29, and .17; P ¼ .016, .001, and .056,
respectively), and low day 84 IgA levels were associated with
subsequent infections (Supplementary Table 6). Also, there
was a correlation between naive B cell counts on day 84 and
IgM, IgG, and IgA levels on day 180 (r ¼ .24, .25, and .31;
P = .001 P = .050
Figure 5. Low IgA level on day 84 associated with subsequent viral infections. Rates of day 84 to 730 viral infections per 365 days at risk in patients with day 84 IgA
levels above and below receiver-operator characteristic determined cutoff are displayed. Shown are the medians and interquartile ranges. Cutoff IgA level is given in
g/L.
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correlation between day 180 B cell counts and day 180 IgA
levels (r ¼ .46, P ¼ .001), and low day 180 IgA levels were
associated with subsequent infections (Supplementary
Table 6).
NK cells in general contribute to defense against infected
cells without need for prior exposure [20]. CD16þCD56low
NK cells kill virus-infected cells by perphorin or granzyme-
mediated cytotoxicity. However, low counts of this
subset were not associated with any or viral infections
(Supplementary Table 2). It was the CD16 CD56high NK
cell subset, low counts of which were associated with
any and probably viral, bacterial, and fungal infections
(Supplementary Table 2). The CD16 CD56high NK cells play
less of a cytotoxic role but instead secrete large amounts of
cytokines including IFN-g in response to IL-12 and IL-15, the
latter being produced by monocytes and dendritic cells
[21,22]. IFN-g activates monocytes [23]. Thus, the following
positive feedback loop may be important for curtailing
infections: Monocytes and dendritic cells secrete IL-12 and
IL-15, which stimulate CD56high NK cells, which in turn
secrete IFN-g, which results in positive feedback stimulation
of monocytes and dendritic cells [24]. Consistent with this
hypothesis, there was a correlation between day 56 CD56high
NK cell counts and counts of monocytes, MDCs, and PDCs
(Supplementary Tables 7 and 8). Additionally, the mono-
cytes, MDCs, and PDCs were also associated with infections
(Supplementary Tables 2, 3, and 4).
We also note an important anomaly of CD56high NK cells:
As opposed to all the other immune cells subsets that we
enumerated, CD56high NK cells are abundant between 1 and
6 months post-transplant (higher counts than in healthy
individuals) [19,25]. Thus, where an association between low
counts of others subsets and infections can be interpreted
as “deﬁciency of the subset predisposes to the infections,”
an association between low CD56high NK cell counts and
infections needs to be interpreted as relative deﬁciency of
CD56high NK cells (fewer cells than what a post-transplant
patient but not a healthy individual should ideally have)
predisposes to the infections.
Low monocytes were also associated with infections,
particularly viral infections (Supplementary Table 3,
Figures 1 and 2). This is consistent with a previous study that
showed low monocyte counts on day 80 to be associated
with an increased rate of subsequent any and viral infections
[26]. Monocytes are known for their role in early defense.They are rapidly recruited to the site of infection and differ-
entiate into macrophages and dendritic cells that stimulate
adaptive immunity [27,28]. The infections were associated
with low counts of inﬂammatory but not resident mono-
cytes, possibly because inﬂammatory monocytes are partic-
ularly efﬁcient in chemotaxis, phagocytosis, and antigen
presentation [29]. In our study the inﬂammatory subset was
associated with fungal infections, which supports previous
evidence that inﬂammatory monocytes orchestrate anti-
fungal immunity in the lungs [30]. Speciﬁcally, this may
occur through the facilitation of CD4 T cells responses
mediated by this inﬂammatory subset of monocytes [31].
Our ﬁnding of an association between total or inﬂammatory
monocyte counts and viral or fungal infections suggests that
monocytes play an important role in antiviral and antifungal
immunity of transplant recipients.
Dendritic cells initiate T cell mediated immune responses
through the presentation of the HLAepeptide complex. PDCs
produce type I interferons (IFN-a and IFN-b) in response to
toll-like receptorevirus engagement [32]. These interferons
in turn block viral replication. Our observation of the asso-
ciation between low PDCs and primarily bacterial infections
(Supplementary Table 6 and Figure 3) suggests that PDCs
may play a role in not only antiviral but also antibacterial
defense. MDCs stimulate T cells, in part through the secretion
of IL-12, which also stimulates NK cells [33]. Per our results,
MDCs appear to play a role in defense against viruses,
bacteria, and fungi (Supplementary Table 6).
Basophil counts were associated with any, deﬁnite,
any severe, and viral infections (Supplementary Table 5 and
Figure 4). Basophils are largely known for their role in
immediate hypersensitivity reactions [34,35]. However, ba-
sophils have been found to also play a role in adaptive hu-
moral immunity [36,37]. Secretion of IgM or a class switch to
IgG or IgA by B cells is enhanced by activated basophils [36].
This is likely mediated through production of IL-4 and IL-6
by the basophils [37]. Therefore, the protective role of
basophils may be via B cell activation/stimulation of anti-
body production. As a side question, post-hoc we wished to
evaluate whether basophil counts determined by the clinical
hematology laboratory were also associated with infections
(as were basophil counts determined by ﬂow cytometry).
There was no signiﬁcant association between the clinical
hematology laboratoryedetermined basophil counts and
infections (data not shown). We speculate that the discrep-
ancy may be due to the higher accuracy of basophil count
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tology laboratory (typically using an automated 5-part
differential analyzer and, in case of ﬂagged results, manual
differential).
Eosinophil counts were associated with any and deﬁnite
infections and, possibly, bacterial and viral infections
(Supplementary Table 5). Although their complete function
is not yet fully understood, eosinophils are widely known
to participate in responses to allergens and helminthes.
However, studies have shown an antiviral effect as well,
speciﬁcally for respiratory viruses [38-40]. Viral activation of
eosinophils may cause their degranulation, whichmay target
the virus or virus-infected cells or may cause resistance
of cells to viral infection [38]. It is also possible that the
presence of a virus stimulates eosinophils to release Th1, Th2,
and regulatory cytokines and chemokines [38,41].
Our study did not ﬁnd any associations between CD4
T cells, CD8 T cells, or total T cells and infections, which has
previously been reported in numerous studies [42-47]. This
lack of associations could be due to the following reasons:
The studies that included patients with GVHD but did not
include GVHD as a covariate may have had positive ﬁndings
because immunosuppressive therapy used for the treatment
of GVHD may have altered (lowered) the T cell count. In our
MVAwe included GHVD as a covariate. Additionally, we may
have had insufﬁcient power to detect the existing association
between low T cell counts and infections.
Given the use of the discovery to validation cohort design,
we can be reasonably conﬁdent in our positive ﬁndings.
However, a disadvantage of our discovery to validation
cohort design is that it has a relatively limited power to
detect weak associations. Thus, in our study a lack of asso-
ciation between a low immune cell subset count and in-
fections should not be interpreted as “deﬁciency of the
subset plays no role in predisposition to infections.” Another
reason this assumptionwould be incorrect is the fact that we
measured the counts of the subsets in the peripheral blood
and not in tissues, where their counts may differ and
presence may be more relevant.
Another limitation of our study is our inability to isolate
the individual contribution of immune cell subsets to the
association with any or deﬁnite infections (Supplementary
Tables 7 and 8). However, this problem pertained only to
days 56 and 84 and not days 28 and 180. Moreover, even for
days 56 and 84 the correlation coefﬁcients between different
immune cell subset counts were relatively low, suggesting
independent contribution of all or most subsets to the
predisposition to infections in general. We considered add-
ing the “competing” subsets as covariates into the MVA;
however, this was not possible because our sample size was
too small for MVAwith more than 3 covariates. Additionally,
with regards to this study limitation, we believe it is more
informative to focus on identifying cell subsets that predis-
pose to a class of pathogens (viruses, bacteria, fungi) rather
than infections in general, as preemptive therapy in the
future would be class-speciﬁc (eg, a future broad-spectrum
antiviral drug for viruses, a broad-spectrum antibacterial
for bacteria, a broad-spectrum antifungal for fungi). For most
class-speciﬁc infections our results are informative: For day
56 subsets and viral infections, only inﬂammatory mono-
cytes and basophils were associated with viral infections
(apart from total monocytes, which are composed mostly of
inﬂammatory monocytes). Because the correlation between
day 56 counts of inﬂammatory monocytes and basophils was
weak (r ¼ .26), deﬁciencies of both inﬂammatory monocytesand basophils likely contribute to the predisposition to viral
infections.
We also acknowledge the frequent use of TBI at our center
may limit the generalizability of our ﬁndings to patients at
centers that use TBI less frequently. It is possible that TBI
could have killed recipient T cells that contribute to antiviral
immunity after HCT [48] or recipient macrophages or den-
dritic cells, which could lead to impaired antigen presenta-
tion to donor T cells.
We conclude that deﬁciency of B cells (primarily naive),
NK cells (primarily CD56high), monocytes (primarily inﬂam-
matory), MDCs, PDCs, basophils, and/or eosinophils may
predispose to postengraftment infections. For viral in-
fections, deﬁciencies of monocytes, basophils, and IgA
plasma cells appear to be the predisposing factors. For bac-
terial infections, PDC deﬁciency appears to be the predis-
posing factor. For fungal infections, inﬂammatory monocyte
deﬁciency appears to be the predisposing factor. Fortunately,
in a previous study we did not ﬁnd high counts of any 1 of
these subsets to be associated with an increased likelihood of
developing GVHD, relapse, or overall mortality [8]. Thus, it
could be studied whether infusion of these subsets (har-
vested from HCT donors) could prevent postengraftment
infections. Studies of infusion of donor CD56high NK cells,
monocytes, PDCs, or basophils would be of particular inter-
est, because high counts of CD56high NK cells, total and
inﬂammatory monocytes, PDCs, and basophils in the ﬁrst
3 months after HCT appear to protect against the develop-
ment of chronic GVHD [8]. Thus, both chronic GVHD and
postengraftment infections could theoretically be prevented.
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